GEHC or A: Which Is the Better Value Stock Right Now?

Zacks research identifies GE HealthCare Technologies (GEHC) as the superior value investment in the Medical - Products sector, assigning it a Zacks Rank #1 (Strong Buy) and a Value grade of B. This assessment is driven by GEHC's more attractive valuation metrics, including a forward P/E of 15.81, PEG ratio of 2.74, and P/B ratio of 3.36, which compare favorably against Agilent Technologies (A), rated Zacks Rank #4 (Sell) with a Value grade of C and higher corresponding ratios.

Analysis

Based on a comparative value analysis within the Medical - Products sector, GE HealthCare Technologies (GEHC) is positioned as a more attractive investment than Agilent Technologies (A). This conclusion is supported by the Zacks Rank system, which assigns GEHC a #1 (Strong Buy) rating, indicative of positive earnings estimate revisions and an improving fundamental outlook. In contrast, Agilent holds a #4 (Sell) rank. On a valuation basis, GEHC appears significantly more compelling, trading at a forward P/E ratio of 15.81 compared to Agilent's 22.47. This valuation advantage extends to growth-adjusted and asset-based metrics, with GEHC's PEG ratio of 2.74 and P/B ratio of 3.36 being notably lower than Agilent's 3.90 and 5.57, respectively. The combination of superior earnings momentum and more favorable valuation multiples underpins GEHC's 'B' Value grade from Zacks, versus a 'C' for Agilent, reinforcing the assessment that GEHC presents a stronger value proposition at current levels.

Key Decisions for Investors

• Value-oriented investors should consider GE HealthCare Technologies as a potentially undervalued opportunity, given its strong earnings momentum (Zacks Rank #1) and significant valuation discount relative to sector peer Agilent Technologies.
• Investors currently holding Agilent Technologies should reassess their position in light of its 'Sell' rating, which signals negative earnings estimate trends, and its comparatively expensive valuation metrics.
• For hedge funds, the diverging fundamentals and valuation gap between the two companies suggest a potential pair trade opportunity, involving a long position in GEHC and a short position in A to capitalize on the contrasting outlooks.